ArticleJGH open : an open access journal of gastroenterology and hepatology2026
Efficacy and Safety of Switching From Intravenous to Subcutaneous Vedolizumab in Japanese Patients With Ulcerative Colitis: A Study Focusing on Injection-Site Reactions.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: The subcutaneous (SC) formulation of vedolizumab is available as an alternative to the intravenous (IV) formulation in patients with ulcerative colitis (UC). However, data from Asian patients are limited, and the clinical course of injection-site reactions (ISRs) remains unclear. This study evaluated the efficacy and safety of switching from IV to SC vedolizumab in Japanese patients with UC, focusing on ISRs. Methods: This retrospective study included patients who switched from IV to SC vedolizumab. The primary outcomes were the incidence and clinical course of ISRs. The secondary outcomes included adverse events other than ISRs, disease activity, remission rates, and treatment persistence. Results: In total, 48 patients were included. The median fecal calprotectin levels remained stable from baseline to 12 months after switching (46.0 vs. 46.0 μg/g), with the fecal calprotectin remission rate remaining stable (41/45, 91% vs. 39/45, 87%). The persistence rate of SC vedolizumab was 98%, and the persistence rate without additional therapy was 94%. ISRs occurred in 29 patients (60%), most frequently within 3-6 months, with a median duration of 4 months. More than half of ISRs improved or resolved by 12 months, and only 11 patients (23%) experienced persistent ISRs. No adverse events other than ISRs were considered likely or probably related to SC vedolizumab. Conclusions: In Asian patients with UC, disease activity was maintained after switching from IV to SC vedolizumab. Although ISRs were common after switching, most were self-limiting. Therefore, switching back to IV formulation solely for ISR management should be cautiously considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.